Supplementary Material for: Study of the Association of <b><i>PEAR1</i></b>,<b><i> P2Y12</i></b>, and <b><i>UGT2A1</i></b> Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients

<b><i>Objectives:</i></b> Genetic variation is thought to contribute to considerable interindividual variability in platelet function, and there is a pressing need to identify genetic markers that can be used to predict the response to treatment. Our study investigated whether <i>PEAR1</i>,<i> P2Y12</i>, and <i>UGT2A1</i> polymorphisms were associated with platelet reactivity in response to dual antiplatelet therapy in Chinese patients with acute coronary syndrome. <b><i>Methods:</i></b> Patients with inhibition of platelet aggregation (IPA) < 30% after treatment were classified as the high platelet reactivity (HPR) group. Patients with IPA > 30% were classified as the normal platelet reactivity (NPR) group. ADP-induced platelet aggregation was measured by thromboelastography (TEG) platelet-mapping assay. Thirteen single nucleotide polymorphisms (SNPs) of <i>PEAR1</i>, <i>P2Y12</i> and <i>UGT2A1</i> were genotyped using the Mass­ARRAY platform. <b><i>Results:</i></b> Seven SNPs were significantly associated with ADP-induced platelet aggregation by univariate analysis. Major allele G at rs12041331, minor allele G at rs2644592, minor allele C at rs11264580, and minor allele C at rs11249454 were significantly associated with HPR, whereas minor allele T at rs57731889, minor allele A at rs16863356, and minor allele T at rs7634096 were significantly associated with NPR. The mean IPA was significantly lower in patients suffering recurrent ischemic events than in patients without recurrent events in our study (<i>p =</i> 0.048). <b><i>Conclusions:</i></b> Our findings suggest that <i>PEAR1</i>,<i> P2Y12</i>, and<i> UGT2A1</i> genetic variants may be potential biomarkers that can be used to guide clinical applications of clopidogrel and aspirin in Chinese patients.